| abstract |
The invention relates to new cetolactam compounds, hydrogenated derivatives and tautomers thereof. These compounds have valuable therapeutic properties and are particularly suitable for treating conditions that respond to dopamine D3 receptor modulation. Cetolactams have the general formula (I), where: (a) represents a group of formulas (b) or (c), where D is linked to the nitrogen atom and W, Rp and Rq have the meanings cited in claim 1, -B- represents a bond or (d), wherein Rm and Rn have the meanings cited in claim 1; (e) represents a single link or a double link; Rv, Rw, Rx, Ry, have the meanings cited in claim 1; D represents a linear or branched 2- to 10-membered alkylene chain which may have, as chain members, a group K of heteroatoms, which is selected from O, S, S (O), S (O) 2, N -R8, CO-O, C (O) NR8 and / or 1 or 2 non-adjacent carbonyl groups and which may have a cycloalkane diyl groups and / or a double or triple bond; (f) represents a heterocyclic nitrogen compound, monocyclic, saturated or monounsaturated, having 5 to 8 cyclic members or a heterocyclic nitrogen compound, saturated, bicyclic, having 7 to 12 cyclic members. |